Department of Hematopoietic Stem Cell Transplantation

Takahiro Fukuda, Sung-Won Kim, Yoshihiro Inamoto, Takashi Tanaka, Ayumu Ito, Jun Aoki, Minoru Kojima

Introduction

We specialize in patients who undergo allogeneic or autologous hematopoietic stem cell transplantation (HSCT). Our transplant units include 26 beds in ward 12B and 3 beds in ward 11A. All rooms are filtered by a central high-efficiency particulate air filtration system.

The Team and What We Do

Seven staff physicians (Drs. Kim, Inamoto, Tanaka, Ito, Aoki, Kojima and Fukuda) participate in the transplant program. Pediatric patients who undergo HSCT are managed in collaboration with Dr. Ogawa, the chief of the Pediatric Oncology Division, and other pediatricians. In fiscal 2021, a total of 102 HSCTs were performed at the 12B and 12A transplant units. The numbers of each type of HCST in fiscal 2021 are shown in Table 1. The numbers of patients according to disease type are shown in Table 2.

We discuss approximately 30 HSCT inpatients and those who consulted us for indication of HSCT every week at the collaborative conference on Monday with the Departments of Hematology and Pediatric Oncology. The transplant unit is staffed by 24 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing team has taken the lead in facilitating improved care for graft-versus-host disease (GVHD), and in providing Long-term Follow-Up (LTFU) care and education for patients and their family members. In fiscal 2021, we saw 373 patients at the LTFU clinic. We discuss all HSCT inpatients in detail among all transplant team members including physicians, nurses, pharmacists, the nutritional support team, rehabilitation team, and mental support team, and the hematopoietic cell transplant coordinator (HCTC) every week on Friday.

Table 1. Number of each type of HSCT


Table 2. Number of patients who underwent HSCT in fiscal 2021

Research activities

We published a phase I/II multicenter trial to determine the safety and efficacy of peripheral blood stem cell transplantation (PBSCT) from an HLA-haploidentical donor with post-transplant cyclophosphamide (PTCY) in patients with aggressive adult T-cell leukemia/lymphoma (ATL) (Tanaka, TCT 2021). We concluded that PBSCT from an HLA-haploidentical donor with PTCY is feasible and promising for patients with aggressive ATL. We started a new phase II multicenter trial to determine the safety and efficacy of PBSCT from an unrelated donor with PTCY in patients with aggressive ATL in March 2021 (Advanced medical care B).

We also published a prospective, observational study to clarify the treatment outcomes of aggressive ATL, which suggest that more frequent application of allo-HSCT improved the survival of patients with aggressive ATL (Ito, Blood Adv 2021). In August 2021, we started patient registration with a nationwide collaborative registry of aggressive ATL patients of all ages in August 2021. By the end of March 2022, 124 patients were registered with the prospective study. In fiscal 2021, we also prepared the construction of a biorepository system with additional support from AMED.

We also published a single-center prospective study to evaluate the adherence to and usefulness of recommended screenings in LTFU (Kurosawa, Sup Care Cancer 2021). We have published a single-center retrospective study to characterize readmission due to HSCT-related complications (Yamaguchi, BMT 2021). The cumulative incidences of readmission were 16% at 100 days and 25% at 1 year after discharge.

 In fiscal 2021, we published 72 articles in peer-reviewed international journals.

Education

We trained 4 residents to develop their clinical skills for management of HSCT patients in fiscal 2021.

Future Prospects

Our goal is to develop optimal strategies of HSCT to cure all patients with hematologic malignancies.

List of papers published

Journal

1. Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, Henzan H, Takase K, Yamasaki S, Makiyama J, Moriuchi Y, Choi I, Nakano N, Hiramoto N, Kato K, Sato T, Sawayama Y, Kim SW, Inoue Y, Inamoto Y, Fukuda T. A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. Transplantation and cellular therapy, 27:928.e1-928.e7, 2021

2. Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, Choi I, Nakamae H, Nagafuji K, Takase K, Machida S, Takahashi T, Sawayama Y, Kamimura T, Kato K, Kawakita T, Ogata M, Sakai R, Shiratori S, Uchimaru K, Inamoto Y, Utsunomiya A, Fukuda T. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood advances, 5:4156-4166, 2021

3. Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Ueno T, Saito Y, Aihara Y, Matsuba Y, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Supportive care in cancer, 30:2767-2776, 2022

4. Yamaguchi K, Inamoto Y, Tajima K, Sakatoku K, Kuno M, Kawajiri A, Takemura T, Tanaka T, Ito A, Kurosawa S, Kim SW, Fukuda T. Characterization of readmission after allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 56:1335-1340, 2021

5. Kasane M, Kurosawa S, Kojima M, Iwashita N, Kase Y, Tsubokura M, Nakabayashi S, Ikeda C, Kawamura K, Matsushita H, Narita R, Fukumoto H, Fujino T, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Ito A, Tanaka T, Inamoto Y, Kim SW, Tajima K, Tanosaki R, Izutsu K, Fukuda T. Usefulness of hematopoietic progenitor cell monitoring to predict autologous peripheral blood stem cell harvest timing: A single-center retrospective study. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis, 60:103150, 2021

6. Ida H, Inamoto Y, Fukuhara S, Maeshima AM, Takeda W, Hirakawa T, Kuno M, Aoki J, Tanaka T, Ito A, Kim SW, Izutsu K, Fukuda T. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma. Hematological oncology, 39:650-657, 2021

7. Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5. Transplantation and cellular therapy, 27:935.e1-935.e9, 2021

8. Kurosawa S, Yamaguchi T, Nakabayashi S, Kasane M, Tsubokura M, Iwashita N, Minakawa Y, Ohtake R, Kawamura K, Nishioka Y, Takeda W, Hirakawa T, Aoki J, Ito A, Tanaka T, Inamoto Y, Kim SW, Kojima M, Takanashi M, Fukuda T. Effect of donor type on volume of blood transfusions required after allogeneic hematopoietic cell transplantation. International journal of hematology, 113:518-529, 2021

9. Inamoto Y, Martin PJ, Onstad LE, Cheng GS, Williams KM, Pusic I, Ho VT, Arora M, Pidala J, Flowers MED, Gooley TA, Lawler RL, Hansen JA, Lee SJ. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Transplantation and cellular therapy, 27:759.e1-759.e8, 2021

10. Nakashima T, Inamoto Y, Aoki J, Ito A, Tanaka T, Kim SW, Hashimoto H, Fukuda T, Furukawa T. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. International journal of hematology, 115:158-162, 2022

11. Nakashima T, Inamoto Y, Fukushi Y, Doke Y, Hashimoto H, Fukuda T, Yamaguchi M. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. International journal of hematology, 113:872-876, 2021

12. Yamagishi M, Kubokawa M, Kuze Y, Suzuki A, Yokomizo A, Kobayashi S, Nakashima M, Makiyama J, Iwanaga M, Fukuda T, Watanabe T, Suzuki Y, Uchimaru K. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nature communications, 12:4821, 2021

13. Kuno M, Yamasaki S, Fujii N, Ishida Y, Fukuda T, Kataoka K, Uchida N, Katayama Y, Sato M, Onai D, Miyamoto T, Ota S, Yoshioka S, Ara T, Hangaishi A, Hashii Y, Onizuka M, Ichinohe T, Atsuta Y, Inamoto Y. Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American journal of hematology, 97:185-193, 2022

14. Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, Miyazaki Y, Ishitsuka K, Sakaida E, Taji H, Wakayama T, Ichinohe T, Fukuda T, Atsuta Y, Kato K, Yoshimitsu M. Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone marrow transplantation, 57:323-325, 2022

15. Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood advances, 6:238-247, 2022

16. Iwasaki M, Kanda J, Tanaka H, Shindo T, Sato T, Doki N, Fukuda T, Ozawa Y, Eto T, Uchida N, Katayama Y, Kataoka K, Ara T, Ota S, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Morishima S. Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation. Frontiers in immunology, 13:811733, 2022

17. Tamaki M, Kameda K, Kimura SI, Harada N, Uchida N, Doki N, Tanaka M, Ikegame K, Sawa M, Katayama Y, Miyakoshi S, Ara T, Kanda J, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Yakushijin K, Nakasone H. Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood advances, 6:1895-1903, 2022

18. Kawajiri A, Kawase T, Tanaka H, Fukuda T, Mukae J, Ozawa Y, Eto T, Uchida N, Mori T, Ashida T, Kondo T, Onizuka M, Ichinohe T, Atsuta Y, Morishima S, Kanda J. Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone marrow transplantation, 57:407-415, 2022

19. Fuji S, Hirakawa T, Takano K, Doki N, Sawa M, Kanda Y, Uchida N, Ara T, Miyamoto T, Eto T, Matsuoka KI, Kawakita T, Ozawa Y, Katayama Y, Onizuka M, Fukuda T, Atsuta Y, Nakasone H. Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone marrow transplantation, 57:479-486, 2022

20. Harada K, Mizuno S, Yano S, Takami A, Ishii H, Ikegame K, Najima Y, Kako S, Ashida T, Shiratori S, Ota S, Onizuka M, Fukushima K, Fukuda T, Ichinohe T, Atsuta Y, Yanada M. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Annals of hematology, 101:643-653, 2022

21. Wada F, Watanabe M, Konuma T, Okabe M, Kobayashi S, Uchida N, Ikegame K, Tanaka M, Sugio Y, Mukae J, Onizuka M, Kawakita T, Kuriyama T, Takahashi S, Fukuda T, Nakano N, Sawa M, Kimura T, Ichinohe T, Atsuta Y, Kanda J. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. American journal of hematology, 97:311-321, 2022

22. Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplantation and cellular therapy, 28:153.e1-153.e11, 2022

23.  Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda J, Morishima S, Uchida N, Doki N, Ikegame K, Ozawa Y, Takada S, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Ichinohe T, Fukuda T, Atsuta Y, Kanda Y. Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and cellular therapy, 28:161.e1-161.e10, 2022

24.  Imahashi N, Terakura S, Kondo E, Kato K, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J, Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J. Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone marrow transplantation, 57:243-251, 2022

25. Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S, Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 36:1132-1138, 2022

26. Akahoshi Y, Kimura SI, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka KI, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S, Nakasone H. Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. Blood advances, 6:574-584, 2022

27. Fuchida SI, Kawamura K, Sunami K, Tsukada N, Fujii S, Ohkawara H, Usuki K, Wake A, Endo S, Ishiyama K, Ueda Y, Nakamura Y, Miyamoto T, Fukuda T, Ichinohe T, Atsuta Y, Takamatsu H. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Transplantation and cellular therapy, 28:76-82, 2022

28. Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Kako S, Tozatto-Maio K, Yanada M, Sanz G, Uchida N, Angelucci E, Kato S, Mohty M, Forcade E, Tanaka M, Sierra J, Ohta T, Saccardi R, Fukuda T, Ichinohe T, Kimura T, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone marrow transplantation, 57:57-64, 2022

29. Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N, Ikegame K, Miyamoto T, Doki N, Nakamae H, Katayama Y, Takahashi S, Shiratori S, Saito S, Kawakita T, Kanda J, Fukuda T, Atsuta Y, Kimura F. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone marrow transplantation, 57:43-50, 2022

30. Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W . Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances, 6:339-357, 2022

31. Williams KM, Inamoto Y, Im A, Hamilton B, Koreth J, Arora M, Pusic I, Mays JW, Carpenter PA, Luznik L, Reddy P, Ritz J, Greinix H, Paczesny S, Blazar BR, Pidala J, Cutler C, Wolff D, Schultz KR, Pavletic SZ, Lee SJ, Martin PJ, Socie G, Sarantopoulos S. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and cellular therapy, 27:452-466, 2021

32. Inoue Y, Nakano N, Fuji S, Eto T, Kawakita T, Suehiro Y, Miyamoto T, Sawayama Y, Uchida N, Kondo T, Kanda J, Atsuta Y, Fukuda T, Yoshimitsu M, Kato K. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. Bone marrow transplantation, 56:2964-2974, 2021

33. Seo S, Usui Y, Matsuo K, Atsuta Y, Igarashi A, Fukuda T, Ozawa Y, Katayama Y, Yoshida S, Uchida N, Kondo T, Kako S, Tsukada N, Kato S, Onizuka M, Ichinohe T, Kimura F, Kanda Y, Miyamura K, Kanda J. Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. Bone marrow transplantation, 56:2410-2422, 2021

34. Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori SI, Mori Y, Morishima Y, Yabe H, Kodera Y. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program. Transplantation and cellular therapy, 27:664.e1-664.e6, 2021

35. Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. Bone marrow transplantation, 56:2231-2240, 2021

36. Inoue T, Koyama M, Kaida K, Ikegame K, Ensbey KS, Samson L, Takahashi S, Zhang P, Minnie SA, Maruyama S, Ishii S, Daimon T, Fukuda T, Nakamae H, Ara T, Maruyama Y, Ishiyama K, Ichinohe T, Atsuta Y, Blazar BR, Furlan SN, Ogawa H, Hill GR. Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. JCI insight, 6:2021

37. Yokoyama H, Hirayama M, Takahashi Y, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Onai D, Katsuoka Y, Wake A, Sawa M, Kobayashi H, Maruyama Y, Ozeki K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Terakura S, Morishima S. Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone marrow transplantation, 56:3059-3067, 2021

38. Kurosawa S, Mizuno S, Arai Y, Masuko M, Kanda J, Kohno K, Onai D, Fukuda T, Ozawa Y, Katayama Y, Tanaka M, Ikegame K, Uchida N, Eto T, Ota S, Tanaka J, Ichinohe T, Atsuta Y, Yanada M. Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. Blood cancer journal, 11:159, 2021

39. Shiratori S, Kurata M, Sugita J, Ota S, Kasahara S, Ishikawa J, Imada K, Onishi Y, Ishiyama K, Ashida T, Kanda Y, Ichinohe T, Fukuda T, Atsuta Y, Teshima T. Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis. Transplantation and cellular therapy, 27:995.e1-995.e6, 2021

40. Yanada M, Konuma T, Yamasaki S, Harada K, Iwasaki M, Kobayashi A, Nishijima A, Tanaka M, Uchida N, Nakamae H, Fukuda T, Onizuka M, Ozawa Y, Sawa M, Katayama Y, Yoshioka S, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yano S. Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplantation and cellular therapy, 27:1005.e1-1005.e8, 2021

41. Kimura SI, Tamaki M, Okinaka K, Seo S, Uchida N, Igarashi A, Ozawa Y, Ikegame K, Eto T, Tanaka M, Shiratori S, Nakamae H, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. Annals of hematology, 100:3029-3038, 2021

42. Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone marrow transplantation, 56:3008-3015, 2021

43.  Fuji S, Hakoda A, Kanda J, Murata M, Terakura S, Inamoto Y, Uchida N, Toya T, Eto T, Nakamae H, Ikegame K, Tanaka M, Kawakita T, Kondo T, Miyamoto T, Fukuda T, Ichinohe T, Kimura T, Atsuta Y, Shintani A, Morishima S. Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone marrow transplantation, 56:2990-2996, 2021

44. Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Fukuda T, Onizuka M, Kimura T, Atsuta Y, Kako S, Yano S. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Annals of hematology, 100:3017-3027, 2021

45. Akahoshi Y, Arai Y, Nishiwaki S, Tachibana T, Shinohara A, Doki N, Uchida N, Tanaka M, Kanda Y, Shiratori S, Ozawa Y, Shono K, Katayama Y, Tanaka J, Fukuda T, Atsuta Y, Kako S. Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. Bone marrow transplantation, 56:2842-2848, 2021

46. Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. International journal of hematology, 114:608-619, 2021

47. Konuma T, Kondo T, Masuko M, Shimizu H, Shiratori S, Fukuda T, Kato J, Sawa M, Ozawa Y, Ota S, Uchida N, Kanda Y, Kako S, Fujisawa S, Fukushima K, Ichinohe T, Atsuta Y, Yanada M. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone marrow transplantation, 56:2779-2787, 2021

48.  Nakamura M, Arai Y, Hirabayashi S, Kondo T, Doki N, Uchida N, Fukuda T, Ozawa Y, Tanaka M, Sawa M, Katayama Y, Kanda Y, Shiratori S, Nakamae H, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y, Kako S. Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. British journal of haematology, 194:403-413, 2021

49.  Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, Kako S, Akahoshi Y, Uchida N, Doki N, Ozawa Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Kimura F. Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. Clinical cancer research: an official journal of the American Association for Cancer Research, 27:4825-4835, 2021

50. Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone marrow transplantation, 56:2302-2304, 2021

51. Hirabayashi S, Uozumi R, Kondo T, Arai Y, Kawata T, Uchida N, Marumo A, Ikegame K, Fukuda T, Eto T, Tanaka M, Wake A, Kanda J, Kimura T, Tabuchi K, Ichinohe T, Atsuta Y, Yanada M, Yano S. Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. Cancer medicine, 10:4250-4268, 2021

52. Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone marrow transplantation, 56:2510-2517, 2021

53. Konuma T, Aoki J, Ozawa Y, Uchida N, Kobayashi T, Onizuka M, Katayama Y, Ohta T, Nakano N, Ota S, Onishi Y, Kobayashi H, Fukuda T, Kanda Y, Atsuta Y. Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation. Transplantation and cellular therapy, 27:671-678, 2021

54. Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T, Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. Leukemia & lymphoma, 62:2514-2520, 2021

55.  Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, Kataoka K, Miyamoto T, Onizuka M, Eto T, Doki N, Ota S, Sato M, Hashii Y, Ichinohe T, Fukuda T, Atsuta Y, Okamoto S, Teshima T. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone marrow transplantation, 56:2355-2366, 2021

56. Harada K, Kimura SI, Fuji S, Najima Y, Yakushijin K, Uchida N, Onizuka M, Ikegame K, Yano S, Shingai N, Matsuoka KI, Onishi Y, Sawa M, Takada S, Kawakita T, Fukuda T, Kanda J, Atsuta Y, Nakasone H. Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation, 56:2183-2193, 2021

57. Ikegame K, Eto T, Ozawa Y, Iwato K, Kanda Y, Atsuta Y, Ogata M, Fukuda T. Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study. Bone marrow transplantation, 56:2125-2136, 2021

58. Mizuno S, Takami A, Kawamura K, Arai Y, Kondo T, Kawata T, Uchida N, Marumo A, Fukuda T, Tanaka M, Ozawa Y, Yoshida S, Ota S, Takada S, Sawa M, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yanada M. Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Transplantation and cellular therapy, 27:314.e1-314.e10, 2021

59. Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada S, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone marrow transplantation, 56:1691-1699, 2021

60. Yanada M, Uchida N, Ichinohe T, Fukuda T, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 56:1720-1722, 2021

61. Uchino K, Vu Quang L, Mizuno S, Horio T, Yamamoto H, Hanamura I, Kodera Y, Luis Espinoza J, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Doki N, Miyamura K, Mori T, Morishita E, Nakao S, Takami A. Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation. Genes and immunity, 22:35-43, 2021

62. Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. International journal of hematology, 113:840-850, 2021

63.  Akahoshi Y, Arai Y, Nishiwaki S, Mizuta S, Marumo A, Uchida N, Kanda Y, Sakai H, Takada S, Fukuda T, Fujisawa S, Ashida T, Tanaka J, Atsuta Y, Kako S. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. International journal of hematology, 113:832-839, 2021

64. Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, Amano I, Ohta T, Miyazaki Y, Kanda J, Fukuda T, Atsuta Y, Kondo E. Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone marrow transplantation, 56:1462-1466, 2021

65. Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, Katayama Y, Shiratori S, Ota S, Matsuoka KI, Onizuka M, Fukuda T, Atsuta Y, Murata M, Terakura S, Nakasone H. Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 73:e620-e628, 2021

66. Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone marrow transplantation, 56:1126-1133, 2021

67. Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers ME, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine JE, Ayuk F, Dignan F, Schoemans H, Tkaczyk E, Farhadfar N, Lawitschka A, Schultz KR, Martin PJ, Sarantopoulos S, Inamoto Y, Socie G, Wolff D, Blazar B, Greinix H, Paczesny S, Pavletic S, Hill G. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and cellular therapy, 27:632-641, 2021

68. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B . Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and cellular therapy, 27:679.e1-679.e8, 2021

69. DeFilipp Z, Couriel DR, Lazaryan A, Bhatt VR, Buxbaum NP, Alousi AM, Olivieri A, Pulanic D, Halter JP, Henderson LA, Zeiser R, Gooley TA, MacDonald KPA, Wolff D, Schultz KR, Paczesny S, Inamoto Y, Cutler CS, Kitko CL, Pidala JA, Lee SJ, Socie G, Sarantopoulos S, Pavletic SZ, Martin PJ, Blazar BR, Greinix HT. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and cellular therapy, 27:729-737, 2021

70.  Sun YC, Inamoto Y, Wang RK, Lee SJ, Hung KF, Shen TT. The disposable bandage soft contact lenses therapy and anterior segment optical coherence tomography for management of ocular graft-versus-host disease. BMC ophthalmology, 21:271, 2021

71. Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood, 138:273-282, 2021

72. Ikegami M, Kohsaka S, Hirose T, Ueno T, Inoue S, Kanomata N, Yamauchi H, Mori T, Sekine S, Inamoto Y, Yatabe Y, Kobayashi H, Tanaka S, Mano H. MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Communications biology, 4:1396, 2021

Book

1. Hashmi SK, Inamoto Y. Late effects post-allogeneic hematopoietic stem cell transplantation. In: Savani BN, Tichelli A (eds), Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant, 2nd Edition, USA, Wiley-Blackwell, 2021

2. Rovó A, Tichelli A, Inamoto Y . Ocular complications. In: Savani BN, Tichelli A (eds), Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant, 2nd Edition, USA, Wiley-Blackwell, 2021